NCT01934790 - Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 22, 2013

Primary Completion Date

June 4, 2015

Study Completion Date

April 12, 2017

Conditions

Prostatic Neoplasms

Interventions

DRUG

Radium-223 dichloride (Xofigo, BAY88-8223)

Participants received intravenous (IV) injection of radium-223 dichloride 50 kBq/kg body weight every 4 weeks up to 6 injections.

Trial Locations (16)

Lørenskog

Bergen

Syracuse

Córdoba

Milan

Málaga

Forlì-Cesena

Omaha

New Orleans

Kuopio

Haifa

Kfar Saba

Petah Tikva

Jerusalem

Barcelona

Umeå